1201186-90-4

Basic information

• Product Name: 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-carbonitrile
• Synonyms: 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-carbonitrile
• CAS NO: 1201186-90-4
• Molecular Weight: 298.325
• Mol File: 1201186-90-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-carbonitrile(1201186-90-4)
• EPA Substance Registry System: 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-carbonitrile(1201186-90-4)

Safety Data

• Hazardous Substances Data: 1201186-90-4(Hazardous Substances Data)

Upstream product

• 1201186-54-0 2-bromo-5-(p-toluenesulfonyl)-5H-pyrrolo[2,3-b]pyrazine 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 557-21-1 dicyanozinc 
• 557-21-1 zinc(II) cyanide 

Downstream Products

• 1201186-92-6 (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)methanamine hydrochloride 
• 1201187-58-7 N-((5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)methyl)cyclohexanecarboxamide 
• 1201187-63-4 1-cyclohexyl-6-tosyl-6H-imidazo[1,5-a]pyrrolo[2,3-e]pyrazine 
• 1201186-09-5 1-cyclohexyl-6H-imidazo[1,5-a]pyrrolo[2,3-e]pyrazine 
• 1308400-74-9 C₂₁H₂₄N₄O₂S₂ 
• 1310704-76-7 (4-methoxyphenyl)(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)methanimine 

Relevant articles and documents

JAK kinase inhibitor, preparation method thereof, and application in the field of medicines

The application relates to a JAK kinase inhibitor, a preparation method thereof, and an application in the field of medicines and belongs to the field of medical chemistry. In the application, a series of novel small-molecular JAK inhibitors are provided and are represented as the general formula (II). The compounds have better effects and higher safety in prevention or treatment on JAK-related adaptation diseases.

Design and synthesis of tricyclic cores for kinase inhibition

Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine. Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest.